JA_Marshfield CO signed 16May24 kw.pdf completed.pdf
PDF 3 MB Posted
- Attached to
- Surveillance Based Lyme Disease Network Federal contract opportunity
- Solicitation number
- 75D30124R73007
About this file
This document is a Justification and Approval (J&A) for Other Than Full and Open Competition for a follow-on contract to provide services in support of the Surveillance Based Lyme Disease Network (SubLyme). The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price purchase order to Marshfield Clinic Research Institute (MCRI) under the authority of FAR 6.302-1. MCRI will provide robust electronic health record-derived data for development of an enhanced surveillance platform for Lyme Disease (LD) and continue work from the previous contract 75D30123C18280. The follow-on contract is a two-year effort valued at $1,062,353.65. CDC has determined MCRI is the only responsible source that can provide the required services, as significant start-up efforts and data have already been established under the previous contract. The contract is not subject to full and open competition due to the need for continuity of services and data delivery. CDC anticipates open competition for future SubLyme network/data acquisition requirements after September 2026.
View the file
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Please wait...
If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.
You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.
For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Template for Justification and Approval for Other Than Full and Open Competition Completion Instructions: The Department of Health and Human Services (HHS) has established a standard template for the preparation of a J&A for Other Than Full and Open Competition. If this is an 8(a) set-aside, please note this form is not required unless the acquisition is valued (including all options) at greater than $22 million. This template is NOT applicable for actions using simplified acquisition procedures (FAR Part 13), Federal Supply Schedule orders (FAR 8.4) or task or delivery orders subject to fair opportunity (FAR 16.505).
Tailor all aspects of this template to the individual acquisition. Consult FAR Subpart 6.3 for guidance. An addendum may be added in case additional space is needed.
When this document is printed, the blue italic instructions are automatically deleted on the printed version.
JUSTIFICATION AND APPROVAL FOR OTHER THAN FULL AND OPEN COMPETITION
2. Description of Action:
Nature:
Pricing:
Funds:
3. Description of Services or Supplies:
Basis for Approval (FAR 6.303-1(d)):
As applicable, briefly describe the services or supplies required to meet the agency's needs, including make & model number where appropriate. Include quantities of supplies or period of performance for services. Provide information for any options included. If the action is a modification to an existing contract, distinguish clearly between the work covered by the original contract and the work to be obtained by the proposed modification.
4. Authority and Rationale: Identify the statutory authority, FAR title and FAR citation permitting other than full and open competition. It may be one of the following most commonly used citations by the operating divisions of the Department of Health and Human Services (HHS), but other exceptions may apply per FAR Subpart 6.3.
Actions other than simplified acquisition procedures (select only one and provide an explanation):
Explain why the intended contractor is the only responsible source who can provide the required supplies or services. Discuss the unique capabilities, expertise, etc. that support the lack of competition/why no other type of supplies or services will satisfy agency requirements. Explain factors/unique qualifications such as proprietary data or exclusive licensing rights, if applicable. When competition is limited to items particular to one manufacturer, this justification must explain why the particular brand name, product, or feature is essential to the Government's requirements, and that market research indicates other companies' similar products, or products lacking the particular feature, do not meet, or cannot be modified to meet the agency's needs in accordance with FAR 11.105. If in connection with a follow-on contract for continued development or production of highly specialized equipment, detail the substantial duplication of cost or unacceptable delays. May not Exceed one year, including all options, unless the head of the agency (Secretary of HHS) determines that exceptional circumstances apply.
If unusual and compelling urgency is the basis for the justification, explain the chronological events leading up to the requirement and explain why time constraints cannot permit even a limited competition. Describe the detrimental effects/serious injury to the mission of the requiring activity or to the government, financial or otherwise, that will result if this justification is not approved. Describe impact of required delivery/performance date. Describe the detrimental effects/serious injury to the mission of the requiring activity or to the government, financial or otherwise, that will result if this justification is not approved and the product or service cannot be provided by the intended sole source contractor. Failure to plan for expiring funds is not a valid reason for citing this exception. May not exceed one year, including all options, unless the head of the agency determines that exceptional circumstances apply.
Provide a citation to the statutory authorization and a brief description of its content, or identify the specified source or other agency.
Provide the authority and citation to the applicable section of FAR 6.3.
Provide a full explanation to justify use of the exception.
5. Agency Actions to Take or Remove Barriers That Led to Other Than Full and Open Competition (If applicable):
Describe the actions, if any, the agency may take to remove or overcome any barriers that led to the restricted consideration prior to any subsequent acquisition for the supplies of services is made. If no such actions have been taken, explain why.
6. Bridge Contracts:
For contract extensions or bridge contracts when a competitive follow-on is in the process of being developed, summarize history of current contract and explain the reasons for any delays in the acquisition. Include discussion of the milestones for the follow-on action; the milestones should be as efficient as possible. Discuss why it would be neither cost effective nor realistic to expect another contractor to perform during the brief interim period; include issues such as start-up costs, phase-in, transfer of GFP, recruitment and staffing, etc. If the action is because of a protest, provide a brief discussion of the protest including the date the protest was filed and the basis of the protest. Explain that the action will provide the minimum quantity or performance period.
7. Actions to Increase Competition:
Describe efforts made to compete the action, including whether a notice was or will be publicized as required by FAR Subpart 5.2 or which exception under FAR 5.202 applies. If a notice was publicized, discuss the number of written responses to the synopsis and the results of the assessment of the written responses. List sources, if any, that expressed, in writing, an interest in the acquisition. Provide rationale if interested sources were rejected. If applicable, state that no other sources have expressed interest, but all offers received shall be considered. Describe what actions will be taken to increase competition before subsequent acquisition of the supplies or services is required. You may state that an action is a one-time requirement, but if a similar requirement arises, every effort will be made to compete it to the maximum extent possible. If action is sole source because of proprietary data or licensing rights and there will be a continuing need for the requirement, there must be evidence that advanced planning has been initiated to overcome the barriers to competition, or there should be documentation to support an analysis that replacement costs/licensing purchase costs outweigh the benefits of competition. If the action is a contract extension or bridge, explain actions to compete the follow-on. If action is an urgent new requirement and a competitive follow-on is anticipated, explain that efforts are underway to facilitate a full and open competition.
8. Market Research:
Describe the extent of the market research conducted to identify all qualified sources and the results thereof. “Market Research” is defined as those attempts you made to ascertain whether other qualified sources exist, and can include contact with knowledgeable experts regarding similar or duplicate requirements, contact with industry, results of a sources sought synopsis, or draft solicitations. Research of the marketplace may consist of written, electronic (i.e. email) telephonic, or world wide web inquiries. Lack of advanced planning is not an acceptable reason for the lack of market research, but true urgency may necessitate abbreviated market research that is limited to readily available historical and commercial information. If action is a contract extension or bridge contract, describe the market research efforts underway or completed for the follow-on. See FAR 10.002(b)(2).
9. Procurement History:
Was action competed?
If action was not competed, state the cited authority, summarize rationale, and describe the actions that were supposed to be taken to increase competition and the results thereof:
10. Additional Information to support the justification:
If applicable, explain why technical packages or specifications to facilitate competition were not developed or available; describe actions taken to remedy the situation.
11. Technical / Requirements Certification: By my signature below, I certify that the supporting data included in this J&A is accurate and complete.
Program Manager Name:
Position Title:
Email address:
Phone:
Program Manager Supervisor (or one level above Program Manager) Name:
Position Title:
Email address:
Signature:
Date:
12. Fair and Reasonable Price/Cost Determination: As Contracting Officer, by my signature below, I hereby determine that the anticipated price/cost to the Government for this contract action will be fair and reasonable.
Provide the basis for this determination, e.g., describe techniques to be used to determine fair and reasonable price (FAR Subpart 15.402), such as price analysis, cost analysis, cost realism. Per FAR Subpart 15.403-4(a)(1), the threshold for obtaining cost or pricing data is $750,000.
Name:
Phone:
Signature:
Date:
13. Contracting Officer's Approval (Required for proposed contract not to exceed $700,000 (value calculated including all options)): I hereby certify that this justification is accurate and complete to the best of my knowledge. I approve this justification subject to availability of funds, and provided that the services and supplies herin describe have otherwise been authorized for acquisition.
Name:
Phone:
Signature:
Date:
14. Legal Review:
All J&As greater than $68 million must have a legal review from the General Law Division of the Office of the General Counsel prior to sending it to the Department.
15. OPDIV Competition Advocate Approval (Required for proposed contract over $700,000 but not exceeding $13.5 million value calculated including all options)):
I have reviewed this justification and find that it adequately supports other than full and open competition.
Name:
Phone:
Signature:
Date:
16. Office of Small and Disadvantaged Business Utilization:
I have reviewed this justification and find that it adequately supports other than full and open competition.
Name:
Phone:
Signature:
Date:
17. OPDIV HCA Approval (Required for proposed contract over $13.5 million but not exceeding $68 million value calculated including all options)):
Name:
Phone:
Signature:
Date:
18. Department Competition Advocate:
Concur:
Non-Concur:
Name:
Phone:
Signature:
Date:
(The below approval paragraph is required if the cumulative contract value, including all options, exceeds $68 million.)
19. HHS Senior Procurement Executive (SPE) Approval:
Based on the foregoing justification, I hereby approve other than full and open competition for the above stated procurement, subject to the availability of funds, and provided that the services herein described have otherwise been authorized for acquisition.
State supplies/services being procured:
State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304:
State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304 Name:
Phone:
Signature:
Date:
11.0.0.20130303.1.892433.887364 Justification & Approval - Other Than Full and Open Competition Health and Human Services Justification & Approval - Other Than Full and Open Competition
| AcquisitionTitle: Surveillance Based Lyme Disease Network (SubLyme), Marshfield |
| Agency: CDC |
| NIHDrop: |
| PSCDrop: |
| PSCOther: |
| AcqusitionYear: 2024 |
| Author: Cindy Summerhawk, COR II |
| CheckBox4: 0 |
| CheckBox5: 1 |
| CheckBox1: 0 |
| Purchase order/contract number: |
| CheckBox8: 1 |
| CheckBox7: 0 |
| CheckBox6: 0 |
| CheckBox9: 0 |
| Agency Actions to Take or Remove Barriers That Led to Fair Opportunity Exception (If applicable): The current contract with Marshfield Clinic was awarded under the FY23 CDC-wide BAA. In accordance with FAR 6.102(d)(2)I), the BAA is a competitive procedure that satisfies the CICA requirement for full and open competition. This follow-on requirement will continue the work for the original contract that was competed through the BAA mechanism. Marshfield Clinic works directly with Westat, the data coordinating center, to provide the necessary EHR data to achieve network goals. Two more years of work by Mashfield Clinic will fulfill all obligations of the work the vendors competed for requirements. Westat is currently funded until September 2026. Openly competing the current requirements at this time will significantly delay meeting the SubLyme Network objectives and Westat's deliverables; data delivery would be delayed for at least one year. CDC anticipates open competition for new SubLyme network/data acquisition after September 2026. |
| CheckBox10: 0 |
| CheckBox11: 0 |
| Other funds: |
| TextField5: Marshfield Clinic Research Institute |
| TextField5: 1000 North Oak Avenue |
| TextField5: Marshfield, WI 54449-5760 |
| CheckBox2: 1 |
| CheckBox3: 0 |
| TextField7: 1,062,353.65 |
| As applicable, briefly describe the services or supplies required to meet the agency's needs, including make & model number where appropriate. Include quantities of supplies or period of performance for services. Provide information for any options included. If the action is a modification to an existing contract, distinguish clearly between the work covered by the basic order and the work to be obtained by the proposed modification.: Marshfield Clinic Research Institute (MCRI) shall provide robust electronic health record-derived data for development of an enhanced surveillance platform for LD. This will encompass follow-on for contract 75D30123C18280. |
MCRI will work with CDC and SubLyme network sites, including the data coordinating center, Westat, regarding the form, format, and content of data deliveries to ensure standardized data collection and reporting.
Task 1. Implement SubLyme network protocol to identify and characterize LD cases based on standardized EHR data within MCRI.
Task 2. Explore data elements that inform clinical manifestations of LD and develop plan for routine monitoring of clinical manifestations (e.g., erythema migrans, arthritis, cardiac complications, neurologic complications) and epidemiology of the disease.
Task 3. Propose research study protocols to conduct clinical research studies to address questions regarding LD in certain patient populations including, but not limited to, pregnant women with LD, those with LD and other tickborne disease coinfections, and those with LD who experience persistent symptoms after treatment.
Task 4. Prepare to conduct LD vaccine impact studies (e.g., coverage, effectiveness, adverse events) once a LD vaccine, or other preventive, is available.
| CheckBox12: 1 |
| State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: This requirement was solicited under the Broad Agency Announcements (BAA) in 2023 which is a competitive mechanism. The requirement was written as a multi-year contract in the Statement of Work (SOW) with a period of performance of 12-months and 4-12 month option periods. However, due to an unforeseen error; the option periods were omitted at award and the SOW was never updated to include the update. The proposal that was submitted was based on the base and option periods that was solicited. |
The intended contractor is the only responsible source who can provide these services because they have been currently providing these services to the government for one year. This requirement was a three-year study and there isn't another source that can provide the continuity of the services. The current work cannot be transferred to a new contractor without significant loss and the government will receive no value. Competing the current requirements at this time will significantly delay meeting the SubLyme network objectives and the loss of money. Therefore, CDC seeks to fund Marshfield Clinic Research Institute, which they are already providing data to the network.
| State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: This is not a bridge contract. |
| State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: The current contract with Marshfield was awarded under the FY23 CDC-wide BAA, and per FAR 6.102(d)(2)(i), the BAA is a competitive procedure that satisfies the CICA requirement for full and open competition. All actions to increase competition and innovation were performed through the original BAA call for white papers and full proposals. CDC anticipates open competition for new SubLyme network requirements after September 2026. Furthermore, a notice of intent to sole source will be posted for 15 days after this J&A is approved. |
| State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: Market research was performed during the BAA review process in FY23 in the form of call for white papers to meet CDC objectives. CDC received thirteen (13) while papers from industry and academia; nine (9) of which were invited to submit proposals and ultimately, CDC selected four (4) vendors: Westat, Geisinger, Marshfield Clinic, and the Mass General Corporation for funding. |
| State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: Market research was performed during the BAA review process in FY23. All vendors were chosen through a highly competitive process. |
| State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: The price will be evaluated utilizing various techniques identified in FAR 14.404-1. This may include, but not limited to, comparison of historical prices, and/or comparison to independent government estimate. The government will obtain certified cost and pricing data to support price negotiation memorandum to support fair and reasonable determination. |
| CheckBox13: 0 |
| CheckBox14: 0 |
| CheckBox15: 0 |
| TextField9: 75D30123C18280 |
| CheckBox16: 1 |
| CheckBox17: 0 |
| Program Manager name: Cindy Summerhawk |
| Program Manager position title: COR |
| Program Manager email address: hrf8@cdc.gov |
| Program Manager phone: 970-225-4240 |
| Program Manager Supervisor name: Ed Cotton |
| Program Manager Supervisor position title: Program Management Officer |
| Program Manager Supervisor email address: euq8@cdc.gov |
| HHS Senior Procurement Executive (SPE) signature: |
| Program Manager Supervisor date: 2024-04-16 |
| Contract Officer's Approval name: Sheena Delaine |
| HHS Senior Procurement Executive (SPE) phone: 770.488.2974 |
| HHS Senior Procurement Executive (SPE) phone: 770-488-8219 |
| HHS Senior Procurement Executive (SPE) phone: 202-7585-124 |
| Contract Officer's Approval date: 2024-05-16 |
| HHS Senior Procurement Executive (SPE) name: Kem Williams |
| HHS Senior Procurement Executive (SPE) name: Gwendolyn S. Miles |
| DateField6: 2024-05-29 |
| Office of Small Business date: 06/03/2024 |
| OPDIV HCA date: |
| Concur with Acquisition: 0 |
| Non-Concur with Acquisition: 0 |
| HHS Senior Procurement Executive (SPE) date: |
| State supplies/services being procured: |
File details come from the government source that posted it. Updated .